

Forum Original Research Communication

Phospholipase A₂, Hydroxyl Radicals, and Lipid Peroxidation in Transient Cerebral Ischemia

RAO MURALIKRISHNA ADIBHATLA,¹⁻³ JAMES F. HATCHER,¹ and ROBERT J. DEMPSEY¹⁻³

ABSTRACT

Phospholipid degradation is an important promoter of neuronal death after transient cerebral ischemia. Phospholipid hydrolysis by phospholipase A₂ (PLA₂) after transient cerebral ischemia releases arachidonic acid. Arachidonic acid metabolism results in formation of reactive oxygen species, lipid peroxides, and toxic aldehydes (malondialdehyde, 4-hydroxynonenal, and acrolein). Citicoline (cytidine-5'-diphosphocholine), an intermediate in phosphatidylcholine synthesis, has undergone 13 phase III clinical trials for stroke, and is being evaluated for treatment of Alzheimer's and Parkinson's diseases. Here we examined the effect of citicoline on PLA₂ activity in relationship to attenuating hydroxyl radical (OH•) generation and lipid peroxidation after transient forebrain ischemia in gerbil. High Ca²⁺ dependency (millimolar range) of PLA₂ activity suggests that secretory PLA₂ is the predominant isoform in membrane and mitochondria. Citicoline attenuated the increase in PLA₂ activity in both membrane and mitochondrial fractions. *In vitro*, citicoline and its components choline and cytidine had no effect on the PLA₂ activity. Thus, citicoline is not a "direct PLA₂ inhibitor." Citicoline also significantly attenuated loss of cardiolipin and arachidonic acid release from phosphatidylcholine and phosphatidylethanolamine. Transient cerebral ischemia resulted in significant formation of OH• and malondialdehyde, and citicoline significantly attenuated their formation. These results suggest that citicoline provides neuroprotection by attenuating the stimulation of PLA₂. *Antioxid. Redox Signal.* 5, 647–654.

INTRODUCTION


FORMATION OF REACTIVE OXYGEN SPECIES (ROS) [superoxide radical (O₂^{-•}), hydrogen peroxide (H₂O₂), and hydroxyl radical (OH•)] and the ensuing oxidation of biological molecules have been proposed to be significant mechanisms of tissue damage in cerebral ischemia and reperfusion (6, 13, 30, 32). Phospholipase A₂ (PLA₂) activation following transient cerebral ischemia releases arachidonic acid from membrane phospholipids. Oxidative metabolism of arachidonic acid is considered to be a significant source of ROS (28, 45). Other important sources include metabolism of xanthine by xanthine oxidase, autooxidation of catecholamines, NADPH

oxidation by neutrophils, and mitochondrial dysfunction (Scheme 1).

H₂O₂ formed by the dismutation of O₂^{-•} is in itself not very reactive, but in the presence of divalent metal ions, particularly Fe²⁺, forms the highly reactive OH• via the Fenton reaction illustrated in Scheme 1 (6). Ferritin has a high affinity for Fe³⁺ at neutral pH, but readily releases iron at pH ≤ 6 (24), for example, by cellular acidosis resulting from excess lactate formation during cerebral ischemia (14, 24, 66). Released Fe³⁺ is reduced by O₂^{-•} to Fe²⁺. During reperfusion, Fe³⁺ in ferritin can also be reduced by O₂^{-•} to Fe²⁺, which is then released due to low affinity of ferritin for Fe²⁺. The OH• in turn induces lipid peroxidation, resulting in formation of

¹Department of Neurological Surgery, ²Cardiovascular Research Center, University of Wisconsin, Madison, WI 53792.

³Veterans Administration Hospital, Madison, WI 53705.



SCHEME 1. Sources of ROS, generation of OH^\bullet , lipid peroxidation, toxic aldehyde formation, and depletion of glutathione (GSH) (3) in ischemia and reperfusion.

toxic aldehydes, malondialdehyde (MDA), 4-hydroxynonenal (HNE), and acrolein (Scheme 1) (21, 61). These aldehydes, particularly HNE and acrolein, covalently bind preferentially to thiols and to a lesser extent to amine groups of proteins and alter their function (33), contributing to neuronal death (23, 52). We have previously shown localization of HNE in the CA_1 region of the hippocampus after transient cerebral ischemia in gerbil (45).

Citicoline (cytidine-5'-diphosphocholine) has provided beneficial effects in various CNS injuries and neurodegenerative diseases, including transient forebrain ischemia, and has undergone several phase III clinical trials (1, 2, 4, 5, 11, 18, 38, 43, 55, 59). However, its mode of action has not been clearly elucidated. It has been suggested that citicoline might affect the PLA_2 activation in cerebral injuries (9, 48), thus providing neuroprotection by attenuating the resultant oxidative damage. Here we examined the effect of citicoline on PLA_2 activity in relationship to attenuating the OH^\bullet generation and lipid peroxidation after transient forebrain ischemia of gerbil.

MATERIALS AND METHODS

Chemicals and reagents

1-Palmitoyl-2-[1- ^{14}C]-arachidonoyl-*sn*-glycero-3-phosphocholine was obtained from Perkin-Elmer Life Sciences (Boston, MA, U.S.A.). Nonradioactive 1-palmitoyl-2-arachidonoyl-*sn*-glycero-3-phosphocholine, 2,3-dihydroxybenzoic acid (2,3-DHBA), 2,5-DHBA, salicylate, protease inhibitor cocktail, malondialdehyde bis(dimethyl acetal), and common reagents were from Sigma Chemical Co. (St. Louis, MO, U.S.A.). HPLC grade solvents and E. Merck silica gel 60 TLC plates were obtained from Fisher Scientific (Pittsburgh, PA, U.S.A.). Citicoline (CDP-choline) was from BioMol (Plymouth Meeting, PA, U.S.A.), and silica gel GHL TLC plates were from Analytich (Newark, DE, U.S.A.).

Induction of transient forebrain ischemia

All surgical procedures were conducted according to the animal welfare guidelines set forth in the NIH *Guide for the Care and Use of Laboratory Animals* (U.S. Department of Health and Human Services Publication 85-23, 1985) and were approved by the animal care committee of the University of Wisconsin-Madison. Male Mongolian gerbils (50–80 g) were anesthetized with 1% halothane in 70:30 $\text{N}_2\text{O}/\text{O}_2$. Both carotid arteries were exposed by a neck incision, oc-

cluded for 10 min, and reperused for up to 3 days (2, 6, 44, 46–48). Citicoline (500 mg/kg i.p., dissolved at 200 mg/ml in saline) was given to gerbils just after the end of ischemia, at 3 h of reperfusion, and daily thereafter until 24 h before euthanasia (3, 44). At the end of the reperfusion period, brains of anesthetized gerbils were frozen *in situ* (3); cortices and hippocampi were dissected at 0°C .

Mitochondria preparation (54)

Hippocampi or cortices were homogenized at 4°C in homogenization buffer (10 mM HEPES, pH 7.4, containing 0.15 M sucrose, 0.5 mM EDTA, 0.5 mM EGTA, and protease inhibitor cocktail). The homogenate was centrifuged at 2,000 g for 3 min and the pellet discarded. The supernatant was centrifuged (12,000 g, 8 min) to obtain the mitochondrial/synaptosomal pellet, which was resuspended in homogenization buffer and centrifuged again (12,000 g, 10 min). The supernatant was discarded, and the pellet was resuspended in 0.25 M sucrose and centrifuged (12,000 g, 10 min) to obtain the mitochondrial fraction. The mitochondrial pellet was resuspended in 0.25 M sucrose.

PLA_2 activity

Hippocampi were homogenized in 10 mM HEPES, pH 7.2, containing 0.5 mM EDTA, 0.5 mM EGTA, and protease inhibitor cocktail, and centrifuged (18,000 g, 10 min). The resulting pellet was resuspended in homogenization buffer and taken as the membrane fraction. PLA_2 activity was determined as the release of [1- ^{14}C]arachidonic acid in a standard reaction mixture containing 100,000 dpm 1-palmitoyl-2-[1- ^{14}C]-arachidonoyl-*sn*-glycero-3-phosphocholine with some modifications (10). The labeled compound was diluted with the corresponding nonlabeled phosphatidylcholine (PtdCho) to give a final concentration of 100 μM in 0.5 ml, prepared by sonication in 100 mM Tris-HCl, pH 8.5, containing 5 mM CaCl_2 and 50% glycerol. These conditions were determined to be optimum for the PLA_2 activity. The reaction was initiated by addition of 0.5 mg of protein (membrane or mitochondria), incubated at 37°C for 30 min, and then terminated by addition of 2 ml of 50 mM acetic acid. Samples were extracted twice with 1.5 ml of CHCl_3 . The CHCl_3 layer containing the substrate and product was dried under nitrogen and redissolved in 50 μl of CHCl_3 /methanol. The entire sample was applied to a silica gel TLC plate, which was developed in petroleum ether/diethyl ether/acetic acid (80:20:1, by volume) to separate [1- ^{14}C]arachidonic acid from the starting material. The band corresponding to the arachidonic acid standard was scraped directly into a scintillation vial and counted. Negative controls included all reagents, with buffer replacing protein in the incubation mixture.

Lipid analysis

Brains of the anesthetized gerbils were frozen *in situ* and hippocampi were subjected to lipid analysis as described earlier (3). In brief, all solvents and extracts were purged with nitrogen during the extraction, TLC, and methylation of lipids. Total lipids were extracted into CHCl_3 /methanol (1:2, vol/vol) containing 0.01% butylated hydroxytoluene. The following

TLC plates and solvent systems (by volume) were used to separate various lipids: (a) PtdCho and phosphatidylethanolamine (PtdEtn): Merck silica gel 60; CHCl₃/methanol/CH₃COOH/HCOOH/water (70:30:14:4:2); (b) Cardiolipin: silica gel GHL, CHCl₃/methanol/CH₃COCH₃/NH₄OH (60:28:20:2.5). The lipids were identified using authentic standards and converted to methyl esters by heating at 70°C for 30 min in 1 ml of methanol containing 20 µl of concentrated sulfuric acid, 0.01% butylated hydroxytoluene, and 10 nmol of heptadecanoic acid (17:0) as internal standard. The methyl esters were extracted into hexane and analyzed with a Hewlett Packard 6890 gas chromatograph.

In vivo trapping of OH•

Thirty minutes following injection of salicylate (300 mg/kg i.p.), anesthetized gerbils were decapitated; the hippocampi were rapidly dissected at 0°C and frozen in liquid nitrogen. Hippocampi were homogenized (purging with nitrogen during this process to avoid any OH• generation) in 70% ethanol containing 0.2 M HClO₄, 0.1 mM EDTA, 0.1 mM sodium metabisulfite, and then centrifuged at 18,000 g. This extracts >95% of salicylate and DHBAs from the tissue, and was found to be superior to previous extraction methods. We found that extraction with aqueous 0.2 M HClO₄ containing 0.1 mM EDTA, 0.1 mM sodium metabisulfite (37) did not quantitatively recover DHBAs and salicylate. Extraction with 100% ethanol (7) recovered DHBAs and salicylate, but also extracted components that eluted near the DHBA retention times in HPLC. The supernatant (300 µl) was mixed with an equal volume of 50 mM sodium acetate/50 mM citric acid, then filtered through a 0.2-µm cellulose acetate filter. The filtrate was injected into an Agilent (formerly Hewlett Packard) 1100 HPLC equipped with an ESA DHBA column and interfaced with an ESA Model 5200A Coulochem II electrochemical detector equipped with a Model 5010 dual-electrode analytical cell. Prior to the analyses, the HPLC was passivated with 6 M nitric acid according to Agilent's recommended procedure to remove trace metals. The electrode potentials were set to 300 mV (electrode 1, DHBAs) and 850 mV (electrode 2, salicylate). The HPLC was run isocratic at 0.5 ml/min with a premixed mobile phase on one channel of the LC pumping system consisting of 50 mM sodium acetate, 50 mM citric acid, 21% methanol, and 4% isopropanol; the pH was adjusted to 2.5 with phosphoric acid after the organic solvents were mixed with the aqueous buffer. Samples were quantitated against external standards of salicylate and 2,3-DHBA. The reaction of salicylate with OH• produces both 2,3-DHBA and 2,5-DHBA. As cytochrome P450 can hydroxylate salicylate to 2,5-DHBA, but not 2,3-DHBA, measurements were based on quantitation of 2,3-DHBA. Data were expressed as the ratio of 2,3-DHBA to salicylate to normalize DHBA levels to varying hippocampi levels of salicylate.

MDA measurements

Lipid peroxidation was determined as 2-thiobarbituric acid (TBA) reactive species (TBARS) (26). MDA forms a chromogenic adduct (2 molecules of TBA + 1 molecule of MDA) with a molar extinction coefficient 153,000 at 535 nm (20). Hippocampi were homogenized at 4°C in 15% trichloroacetic

acid, then 0.75% TBA in 0.5% sodium acetate was added, and the sample was incubated at 70°C for 45 min. After cooling to room temperature, TBARS were extracted into *n*-butanol, and the absorbance was read at 535 nm. The MDA concentration was calculated against a standard curve using malondialdehyde bis(dimethyl acetal).

RESULTS

PLA₂ activity was measured over the range of 0–25 mM Ca²⁺ in the assay buffer to determine the calcium requirement for PLA₂ in gerbil brain. To obtain sufficient mitochondria, pooled cortices and pooled hippocampi from ischemic gerbils were used. Figure 1 shows the Ca²⁺ dependency of PLA₂ activity in membrane and mitochondrial fractions. The Ca²⁺ response was similar between mitochondria from cortex or hippocampus. Membrane and mitochondria also showed similar Ca²⁺ response toward the PLA₂ activity. Very little PLA₂ activity was detected in the absence of Ca²⁺. Maximum activity was observed at 5 mM Ca²⁺, and subsequent experiments used this concentration for the rest of the PLA₂ studies.

Following 10-min ischemia and over 24-h reperfusion period, hippocampal PLA₂ activity significantly increased in both membrane ($p < 0.05$) and mitochondrial ($p < 0.01$) fractions (Fig. 2). The increase in the mitochondria was greater than in the membrane fraction. Citicoline treatment resulted in significant decreases ($p < 0.05$ and $p < 0.01$) in PLA₂ activity in membrane and mitochondria. PLA₂ activity in membrane and mitochondrial fractions after 10-min ischemia with no reperfusion (10-min permanent ischemia) were 47.8 ± 6.1 and 73.4 ± 1.6 pmol/min/mg of protein, respectively.

The increase in PLA₂ activity in membrane and mitochondria was reflected in a decrease in the arachidonic acid content (expressed as percentage of total fatty acids) of PtdCho and PtdEtn, and a decrease in the cardiolipin levels at 24-h reperfusion following 10-min ischemia (Table 1). Citicoline (500 mg/kg at 0- and 3-h reperfusion) significantly restored




FIG. 1. Ca²⁺ dependency of PLA₂ activity in membrane (dashed line) and mitochondria (solid line) from ischemic gerbil hippocampus. Average of $n = 3$ experiments and typical standard deviation are shown.




FIG. 2. Effect of citicoline on PLA₂ activity in gerbil hippocampal membrane and mitochondrial fractions after transient forebrain ischemia (*n* = 5 animals per group). ^a*p* < 0.05 and ^b*p* < 0.01, compared with sham; ^c*p* < 0.05 and ^d*p* < 0.01, compared with saline-treated ischemic group.

cardiolipin levels and the arachidonic acid content in PtdCho and PtdEtn.

To determine OH• radical generation following transient cerebral ischemia and effect of citicoline, 2-hydroxybenzoic acid (salicylic acid) trapping was used and the formation of 2,3-DHBA was quantitated by HPLC with electrochemical detection. Figure 3A shows the HPLC profiles of 2,5-DHBA, 2,3-DHBA, and salicylate after 10-min ischemia and 24-h reperfusion. The authenticity of the peaks was confirmed in comparison with the standards (Fig. 3B). No peaks corresponding to DHBA or salicylate were detected in hippocampal extracts of gerbils that were not treated with salicylate (data not shown). Based on this method, OH• formation was significantly




FIG. 3. HPLC profile of (A) 2,5-DHBA and 2,3-DHBA and salicylic acid standards and (B) 10-min ischemia and 24-h reperfusion in gerbil. (C) OH• formation in gerbil hippocampus over 3 days of reperfusion after 10-min forebrain ischemia measured by salicylate trapping and effect of citicoline (*n* = 5 per group). ^a*p* < 0.01, compared with sham; ^b*p* < 0.05, compared with saline-treated ischemic group.

increased in gerbil hippocampus following 10 min of ischemia and over 3 days of reperfusion (Fig. 3C). OH• generation was significantly attenuated by citicoline, but did not return to sham levels (Fig. 3C). MDA levels (an indicator for lipid peroxidation) were significantly elevated over 3 days of

TABLE 1. EFFECT OF CITICOLINE ON ARACHIDONIC ACID (20:4) COMPOSITION OF PTDCHO AND PTDETN AND ON CARDIOLIPIN FOLLOWING FOREBRAIN ISCHEMIA AND 24-H REPERFUSION IN GERBIL HIPPOCAMPUS

	Arachidonic (20:4) (% of total fatty acids)		Cardiolipin (μmol of fatty acids/g of tissue)	
	PtdCho	PtdEtn	Arachidonic acid	Total
Sham (<i>n</i> = 12 animals)	6.1 ± 0.45	15.8 ± 0.97	0.22 ± 0.07	1.60 ± 0.29
Sham + citicoline (<i>n</i> = 8)	6.3 ± 0.51	15.9 ± 0.83	0.21 ± 0.07	1.54 ± 0.26
I/24-h R (<i>n</i> = 8)	5.0 ± 0.39*	12.9 ± 0.49*	0.16 ± 0.05	1.25 ± 0.17*
I/24-h R + citicoline (<i>n</i> = 8)	6.0 ± 0.37‡	15.0 ± 0.46‡	0.21 ± 0.05	1.63 ± 0.20‡

**p* < 0.01, compared with sham; ‡*p* < 0.01, compared with saline-treated ischemia (I) and 24-h reperfusion (R).

reperfusion after transient ischemia, and citicoline significantly attenuated these ($p < 0.05$ compared with saline), but did not return MDA to sham levels (Fig. 4).

DISCUSSION

Phospholipid degradation due to the activation of phospholipases is an important promoter of neuronal death after cerebral ischemia/reperfusion. Expression of PLA₂ mRNA has been demonstrated in both neurons and glia (31). Increased PLA₂ immunoreactivity demonstrated a precise overlap with neuropathological changes in several types of CNS injury, including focal and global cerebral ischemia (16, 60). PLA₂ immunoreactivity was increased in the hippocampal CA₁ region undergoing neuronal death (16, 60, 62). PLA₂ isozymes occur in multiple forms in the mammalian cell and are classified as calcium independent, cytosolic (cPLA₂), and secretory (sPLA₂) (39, 58, 65). Transgenic 129/Sv mice deficient in cPLA₂ developed smaller infarcts after transient ischemia (12). Interestingly, this mouse strain is spontaneously deficient in type II sPLA₂ due to a point mutation in exon 3 of the gene encoding sPLA₂ protein (29, 35). Hence, the 129/Sv cPLA₂ transgenic mice (12) were deficient in both cPLA₂ and sPLA₂, but still developed infarcts, consistent with ischemic injury being multidimensional, and PLA₂ contributing to neuronal damage after ischemia and reperfusion.

We selected 1-palmitoyl-2-arachidonoyl-*sn*-glycero-3-phosphocholine as the substrate for the PLA₂ assay because PtdCho containing arachidonic acid in the *sn*-2 position is the preferred substrate for cPLA₂, and with the expectation that there would be significant changes in cPLA₂ activity in the hippocampus following transient forebrain ischemia. Although the preferred substrate for sPLA₂ is PtdEtn, sPLA₂ has no preference for the fatty acid in the *sn*-2 position and also acts on PtdCho (39). Thus, activities of both forms of PLA₂ (cPLA₂ and sPLA₂) could be determined using this substrate.




FIG. 4. MDA levels, an indicator of lipid peroxidation, in the hippocampus over 3 days of reperfusion and effect of citicoline following 10-min forebrain ischemia ($n = 5$ per group). ^a $p < 0.01$, compared with sham; ^b $p < 0.05$, compared with saline-treated ischemic group.

cPLA₂ is stimulated by micromolar Ca²⁺ concentrations, whereas sPLA₂ requires millimolar Ca²⁺ for optimal activity. Based on the Ca²⁺ dependency of PLA₂ activity (Fig. 1), the predominant isoform present in gerbil hippocampus is sPLA₂. In the absence of Ca²⁺, there was very little PLA₂ activity, indicating that there is no significant amount of the Ca²⁺-independent form. There was very little increase in PLA₂ activity at 10–100 μ M Ca²⁺, the range where cPLA₂ is activated, suggesting that this isoform is also present in gerbil hippocampus at very low concentrations. In this regard, it has been reported that the level of cPLA₂ in rat brain is very low (65). Our results are consistent with those of a previous report (50) demonstrating that the major PLA₂ in mitochondria of gerbil brain has a molecular mass of 14 kDa, characteristic of sPLA₂. Previous studies indicate that the mitochondrial PLA₂ is a group IIA isoform that acts on PtdCho, PtdEtn, and cardiolipin (40, 67). sPLA₂ activity increased in the membrane and mitochondrial fractions of the hippocampus over 24 h of reperfusion (Fig. 2).

Citicoline treatment *in vivo* resulted in a decrease in PLA₂ activity in both membrane and mitochondrial fractions (Fig. 2). It is unlikely that citicoline attenuated PLA₂ activity by directly inhibiting the enzyme, because *in vitro*, citicoline and its components choline and cytidine at 0.5 mM in the PLA₂ assay had no effect on the enzyme activity and, as such, citicoline is not a PLA₂ inhibitor (1). It has been suggested that citicoline prevented the activation of mitochondrial PLA₂ (9, 48). However, “preventing the activation” has sometimes been misinterpreted as “PLA₂ inhibition.” As citicoline does not directly inhibit PLA₂, our data suggest that citicoline may act on upstream events that regulate sPLA₂. It is not known if the effect of citicoline on sPLA₂ involves phosphorylation. Although cPLA₂ is activated by phosphorylation, it has been generally believed that sPLA₂ isoforms in general lack phosphorylation sites (19). However, a recent study reported significant stimulation of PLA₂ activity by phosphorylation *in vitro* of a purified type IIA sPLA₂ by casein kinase (57). It has been shown that proinflammatory cytokines such as tumor necrosis factor- α (TNF- α) are induced in gerbil hippocampus at 1–6 h and 24 h following transient ischemia (51). TNF- α has been shown to regulate expression of sPLA₂ (8, 56) and caspase activation (41). The stimulation of PLA₂ by TNF- α can be mediated through PLA₂ activating protein (15, 49).

Inhibition of PLA₂ attenuated TNF- α cytotoxicity (25, 64), indicating that PLA₂ mediates TNF- α cytotoxic signaling. TNF- α has also been shown to inhibit cytidine triphosphate phosphocholine cytidyltransferase (PCCT) (36), the rate-limiting enzyme in PtdCho synthesis. Thus, increases in TNF- α may simultaneously stimulate PtdCho hydrolysis and inhibit its synthesis. Inhibition of PtdCho synthesis is sufficient in itself to cause cell death (17). However, the role of TNF- α in PLA₂ induction and lipid metabolism in cerebral ischemia has not been demonstrated. It was recently shown that citicoline decreased activation of caspases and poly(ADP-ribose) polymerase-cleaved products of caspase activation after focal cerebral ischemia (34). It is possible that citicoline prevented stimulation of sPLA₂ and caspase activation by attenuating induction of TNF- α , although the precise entry point of citicoline in the sequence of events following cerebral ischemia is not yet clear. We hypothesize that TNF- α is responsible for

the loss of PtdCho through modulation of PLA₂ (8), PtdCho-specific phospholipase C (53), and PCCT (36) following transient cerebral ischemia (Scheme 2).

Our studies demonstrated significant decrease in the arachidonic acid composition of PtdCho and PtdEtn and loss of cardiolipin in the gerbil hippocampus following ischemia and 24 h of reperfusion, which were prevented by citicoline treatment (Table 1). Cardiolipin is an exclusive inner mitochondrial phospholipid enriched with unsaturated fatty acids and is essential for mitochondrial electron transport (30); its loss could disrupt the mitochondrial respiratory chain, resulting in increased ROS generation. Citicoline may have prevented hydrolysis of PtdCho, PtdEtn, and cardiolipin by attenuating stimulation of sPLA₂.

Our studies also demonstrated an increase in OH• generation at 24 h of reperfusion after forebrain ischemia (Fig. 3C). Citicoline treatment decreased formation of OH•. Citicoline has been described as an antioxidant or free-radical scavenger (27), but this apparently was based on the ability of citicoline to attenuate arachidonic acid release. There is no evidence that citicoline directly interacts with or detoxifies oxygen radicals. TNF-α increases generation of ROS, which is mediated by stimulation of PLA₂ (63). The decrease in OH• may reflect the effects of citicoline on TNF-α and/or sPLA₂, thus decreasing mitochondrial dysfunction and limiting the amount of arachidonic acid available for oxidative metabolism by cyclooxygenases/lipoxygenases, pathways that generate ROS (Scheme 1). Citicoline did not bring the OH• generation to sham levels, indicating that other pathways also contribute to ROS generation.

Citicoline also attenuated the increased levels of MDA (Fig. 4) and conjugated dienes (22), indicators of lipid peroxidation, following transient cerebral ischemia. The effect of citicoline on MDA was greater than its effect on OH• (Fig. 3C). This may be due to the fact that MDA levels reflect accumulation of the aldehyde over time and/or detoxification by glutathione S-transferase, whereas the 2,3-DHBA/salicylate ratio is a measure at a specific time point of OH• levels, which cannot accumulate due to its extreme reactivity. We have also shown in the past that citicoline treatment increased the total glutathione and glutathione reductase activity and decreased the glutathione oxidation ratio, an indicator of glutathione redox status (3).

A transgenic derivative of the mouse strain C57BL/6 has been developed that expresses type II sPLA₂ to compensate

for the defective gene in the “normal” C57BL/6 (42), which might provide an interesting model to assess the role of sPLA₂ in ischemic brain injury.

In conclusion, citicoline neuroprotection in cerebral ischemia (1, 44) may be partly due to limiting the stimulation of PLA₂, resulting in a decrease in hydrolysis of phospholipids such as PtdCho, PtdEtn, and cardiolipin, thereby limiting the ROS generation and lipid peroxidation.

ACKNOWLEDGMENTS


This study was supported by grants from National Institutes of Health (NIH/NINDS RO1 NS42008), Department of Neurological Surgery and Medical School Research Grant (161-9904) from University of Wisconsin to R.M.A., and American Heart Association Northland Affiliate Grant-in-Aid (0350601Z) to R.J.D., and resources provided by VA Hospital, Madison, WI.

ABBREVIATIONS

citicoline, cytidine-5'-diphosphocholine; cPLA₂, cytosolic phospholipase A₂; DHBA, dihydroxybenzoic acid; HNE, 4-hydroxynonenal; H₂O₂, hydrogen peroxide; MDA, malondialdehyde; O₂^{•-}, superoxide anion radical; OH•, hydroxyl radical; PCCT, cytidine triphosphate phosphocholine cytidyltransferase; PLA₂, phospholipase A₂; PtdCho, phosphatidylcholine; PtdEtn, phosphatidylethanolamine; ROS, reactive oxygen species; sPLA₂, secretory phospholipase A₂; TBA, 2-thiobarbituric acid; TBARS, 2-thiobarbituric acid reactive species; TNF-α, tumor necrosis factor-α.

REFERENCES

- Adibhatla RM and Hatcher JF. Citicoline mechanisms and clinical efficacy in cerebral ischemia. *J Neurosci Res* 70: 133–139, 2002.
- Adibhatla RM and Hatcher JF. Citicoline decreases phospholipase A₂ stimulation and hydroxyl radical generation in transient cerebral ischemia. *J Neurosci Res* 73: 308–315, 2003.
- Adibhatla RM, Hatcher JF, and Dempsey RJ. Effects of citicoline on phospholipid and glutathione levels in transient cerebral ischemia. *Stroke* 32: 2376–2381, 2001.
- Adibhatla RM, Hatcher JF, and Dempsey RJ. Citicoline: mechanisms and stroke clinical trials. *Neurology* <http://www.neurology.org/cgi/eletters/57/9/1595>, 2002.
- Adibhatla RM, Hatcher JF, and Dempsey RJ. Citicoline: neuroprotective mechanisms in cerebral ischemia. *J Neurochem* 80: 12–23, 2002.
- Adibhatla RM, Hatcher JF, Sailor KA, and Dempsey RJ. Polyamines and CNS injury: spermine and spermidine decrease following transient focal cerebral ischemia in spontaneously hypertensive rats. *Brain Res* 938: 81–86, 2002.
- Althaus JS, Andrus PK, Williams CM, von Voigtlander PF, Cazars AR, and Hall ED. The use of salicylate hydroxyla-



SCHEME 2. Proposed action of citicoline on TNF-α-mediated events after transient cerebral ischemia (8, 36, 52). PCCT (36) is the rate-limiting enzyme of PtdCho synthesis. ↑ = increase, ↓ = decrease. PtdCho-PLC, PtdCho-specific phospholipase C.

- tion to detect hydroxyl radical generation in ischemic and traumatic brain injury. *Mol Chem Neuropathol* 20: 147–161, 1993.
8. Anthonen MW, Solhaug A, and Johansen B. Functional coupling between secretory and cytosolic phospholipase A₂ modulates tumor necrosis factor- α - and interleukin-1 β -induced NF- κ B activation. *J Biol Chem* 276: 30527–30536, 2001.
 9. Arrigoni E, Averet N, and Cohadon F. Effects of CDP-choline on phospholipase A₂ and cholinephosphotransferase activities following a cryogenic brain injury in the rabbit. *Biochem Pharmacol* 36: 3697–3700, 1987.
 10. Basavarajappa BS, Saito M, Cooper TB, and Hungund BL. Activation of arachidonic acid-specific phospholipase A₂ in human neuroblastoma cells after chronic alcohol exposure: prevention by GM1 ganglioside. *Alcohol Clin Exp Res* 21: 1199–1203, 1997.
 11. Baskaya MK, Dogan A, Rao AM, and Dempsey RJ. Neuroprotective effects of citicoline on brain edema and blood-brain barrier breakdown after traumatic brain injury. *J Neurosurg* 92: 448–452, 2000.
 12. Bonventre JV, Huang ZH, Taheri MR, O'Leary E, Li E, Moskowitz MA, and Sapirstein A. Reduced fertility and postischemic brain injury in mice deficient in cytosolic phospholipase A₂. *Nature* 390: 622–625, 1997.
 13. Chan PH. Reactive oxygen radicals in signaling and damage in the ischemic brain. *J Cereb Blood Flow Metab* 21: 2–14, 2001.
 14. Chi SI, Wang CK, Chen JJ, Chau LY, and Lin TN. Differential regulation of H- and L-ferritin messenger RNA subunits, ferritin protein and iron following focal cerebral ischemia-reperfusion. *Neuroscience* 100: 475–484, 2000.
 15. Clark MA, Chen MJ, Crooke ST, and Bomalaski JS. Tumor necrosis factor (cachectin) induces phospholipase A₂ activity and synthesis of a phospholipase A₂-activating protein in endothelial cells. *Biochem J* 250: 125–132, 1988.
 16. Clemens JA, Stephenson DT, Smalstig EB, Roberts EF, Johnstone EM, Sharp JD, Little SP, and Kramer RM. Reactive glia express cytosolic phospholipase A₂ after transient global forebrain ischemia in the rat. *Stroke* 27: 527–535, 1996.
 17. Cui Z, Houweling M, Chen MH, Record M, Chap H, Vance DE, and Terce F. A genetic defect in phosphatidylcholine biosynthesis triggers apoptosis in Chinese hamster ovary cells. *J Biol Chem* 271: 14668–14671, 1996.
 18. Davalos A, Castillo J, Alvarez-Sabin J, Secades JJ, Mercadal J, Lopez S, Cobo E, Warach S, Sherman D, Clark WM, and Lozano R. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. *Stroke* 33: 2850–2857, 2002.
 19. Dennis EA. Diversity of group types, regulation, and function of phospholipase A₂. *J Biol Chem* 269: 13057–13060, 1994.
 20. Esterbauer H. Estimation of peroxidative damage: a critical review. *Pathol Biol (Paris)* 44: 25–28, 1996.
 21. Esterbauer H, Schaur RJ, and Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. *Free Radic Biol Med* 11: 81–128, 1991.
 22. Festa M, Puglisi G, Giacom CD, and Russo A. Liposomes as in vivo carriers for citicoline: effects on rat cerebral post-ischemic reperfusion. *J Pharm Pharmacol* 46: 974–981, 1994.
 23. Green DR and Reed JC. Mitochondria and apoptosis. *Science* 281: 1309–1312, 1998.
 24. Hall ED. Lipid peroxidation. In: *Primer on Cerebrovascular Disease*, edited by Welch KMA, Caplan LR, Reis DJ, Siesjo BK, and Wier B. San Diego: Academic Press, 1997, pp. 200–204.
 25. Hayakawa M, Ishida N, Takeuchi K, Shibamoto S, Hori T, Oku N, Ito F, and Tsujimoto M. Arachidonic acid-selective cytosolic phospholipase A₂ is crucial in the cytotoxic action of tumor necrosis factor. *J Biol Chem* 268: 11290–11295, 1993.
 26. Jentzsch AM, Bachmann H, Furst P, and Biesalski HK. Improved analysis of malondialdehyde in human body fluids. *Free Radic Biol Med* 20: 251–256, 1996.
 27. Kasner SE and Grotta JC. Emergency identification and treatment of acute ischemic stroke. *Ann Emerg Med* 30: 642–653, 1997.
 28. Katsuki H and Okuda S. Arachidonic acid as a neurotoxic and neurotrophic substance. *Prog Neurobiol* 46: 607–636, 1995.
 29. Kennedy BP, Payette P, Mudgett J, Vadas P, Pruzanski W, Kwan M, Tang C, Rancourt DE, and Cromlish WA. A natural disruption of the secretory group II phospholipase A₂ gene in inbred mouse strains. *J Biol Chem* 270: 22378–22385, 1995.
 30. Kirkland RA, Adibhatla RM, Hatcher JF, and Franklin JL. Loss of cardiolipin and mitochondria during programmed neuronal death: evidence of a role for a lipid peroxidation and autophagy. *Neuroscience* 115: 587–602, 2002.
 31. Kishimoto K, Matsumura K, Kataoka Y, Morii H, and Watanabe Y. Localization of cytosolic phospholipase A₂ messenger RNA mainly in neurons in the rat brain. *Neuroscience* 92: 1061–1077, 1999.
 32. Kontos HA. Oxygen radicals in cerebral ischemia. *Stroke* 32: 2712–2716, 2001.
 33. Kruman I, Bruce-Keller AJ, Bredesen D, Waeg G, and Mattson MP. Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. *J Neurosci* 17: 5089–5100, 1997.
 34. Krupinski J, Ferrer I, Barrachina M, Secades JJ, Mercadal J, and Lozano R. CDP-choline reduces pro-caspase and cleaved caspase-3 expression, nuclear DNA fragmentation, and specific PARP-cleaved products of caspase activation following middle cerebral artery occlusion in the rat. *Neuropharmacology* 42: 846–854, 2002.
 35. MacPhee M, Chepenik KP, Liddell RA, Nelson KK, Siracusa LD, and Buchberg AM. The secretory phospholipase A₂ gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. *Cell* 81: 957–966, 1995.
 36. Mallampalli RK, Ryan AJ, Salome RG, and Jackowski S. Tumor necrosis factor- α inhibits expression of CTP:phosphocholine cytidyltransferase. *J Biol Chem* 275: 9699–9708, 2000.
 37. McCabe DR, Maher TJ, and Acworth IN. Improved method for the estimation of hydroxyl free radical levels in vivo based on liquid chromatography with electrochemical detection. *J Chromatogr* 691: 23–32, 1997.

38. Mir C, Clotet J, Aleido R, Durany N, Argemí J, Lozano R, Cervós-Navarro J, and Casals N. CDP-choline prevents glutamate-mediated cell death in cerebellar granule neurons. *J Mol Neurosci* 20: 53–56, 2003.
39. Murakami M and Kudo I. Phospholipase A₂. *J Biochem (Tokyo)* 131: 285–292, 2002.
40. Nakahara I, Kikuchi H, Taki W, Nishi S, Kito M, Yonekawa Y, Goto Y, and Ogata N. Changes in major phospholipids of mitochondria during postischemic reperfusion in rat brain. *J Neurosurg* 76: 244–250, 1992.
41. Nau R and Bruck W. Neuronal injury in bacterial meningitis: mechanisms and implications for therapy. *Trends Neurosci* 25: 38–45, 2002.
42. Nevalainen TJ, Laine VJO, and Grass DS. Expression of human group II phospholipase A₂ in transgenic mice. *J Histochem Cytochem* 45: 1109–1120, 1997.
43. Plataras C, Angelogianni P, and Tsakiris S. Effect of CDP-choline on hippocampal acetylcholinesterase and Na⁺,K⁺-ATPase in adult and aged rats. *Z Naturforsch [C]* 58: 277–281, 2003.
44. Rao AM, Hatcher JF, and Dempsey RJ. CDP-choline: neuroprotection in transient forebrain ischemia of gerbils. *J Neurosci Res* 58: 697–705, 1999.
45. Rao AM, Hatcher JF, and Dempsey RJ. Lipid metabolism in ischemic neuronal death. *Recent Res Dev Neurochem* 2: 533–549, 1999.
46. Rao AM, Hatcher JF, Kindy MS, and Dempsey RJ. Arachidonic acid and leukotriene C₄: role in transient cerebral ischemia of gerbils. *Neurochem Res* 24: 1225–1232, 1999.
47. Rao AM, Hatcher JF, and Dempsey RJ. Lipid alterations in transient forebrain ischemia: possible new mechanisms of CDP-choline neuroprotection. *J Neurochem* 75: 2528–2535, 2000.
48. Rao AM, Hatcher JF, and Dempsey RJ. Does CDP-choline modulate phospholipase activities after transient forebrain ischemia? *Brain Res* 893: 268–272, 2001.
49. Ribardo DA, Crowe SE, Kuhl KR, Peterson JW, and Chopra AK. Prostaglandin levels in stimulated macrophages are controlled by phospholipase A₂-activating protein and by activation of phospholipase C and D. *J Biol Chem* 276: 5467–5475, 2001.
50. Rordorf G, Uemura Y, and Bonventre JV. Characterization of PLA₂ activity in gerbil brain: enhanced activities of cytosolic, mitochondrial, and microsomal forms after ischemia and reperfusion. *J Neurosci* 11: 1829–1836, 1991.
51. Saito K, Suyama K, Nishida K, Sei Y, and Basile AS. Early increases in TNF- α , IL-6 and IL-1- β levels following transient cerebral ischemia in gerbil brain. *Neurosci Lett* 206: 149–152, 1996.
52. Sastry PS and Rao KS. Apoptosis and the nervous system. *J Neurochem* 74: 1–20, 2000.
53. Schutze S, Berkovic D, Tomsing O, Unger C, and Kronke M. Tumor necrosis factor induces rapid production of 1',2'-diacylglycerol by a phosphatidylcholine-specific phospholipase C. *J Exp Med* 174: 975–988, 1991.
54. Sciamanna MA and Lee CP. Ischemia/reperfusion-induced injury of forebrain mitochondria and protection by ascorbate. *Arch Biochem Biophys* 305: 215–224, 1993.
55. Secades JJ. CDP-choline: update and review of its pharmacology and clinical use. *Methods Find Exp Clin Pharmacol* 24 (Suppl. B): 1–53, 2002.
56. Seeds MC, Jones DF, Chilton FH, and Bass DA. Secretory and cytosolic phospholipases A₂ are activated during TNF priming of human neutrophils. *Biochim Biophys Acta* 1389: 273–284, 1998.
57. Shimoyama Y, Sakamoto R, Akaboshi T, Tanaka M, and Ohtsuki K. Characterization of secretory type IIA phospholipase A₂ (sPLA₂-IIA) as a glycyrrhizin (GL)-binding protein and the GL-induced inhibition of the CK-II-mediated stimulation of sPLA₂-IIA activity in vitro. *Biol Pharm Bull* 24: 1004–1008, 2001.
58. Six DA and Dennis EA. The expanding superfamily of phospholipase A₂ enzymes: classification and characterization. *Biochim Biophys Acta* 1488: 1–19, 2000.
59. Sobrado M, Lopez MG, Carceller F, Garcia AG, and Roda JM. Combined nimodipine and citicoline reduce infarct size, attenuate apoptosis and increase bcl-2 expression after focal cerebral ischemia. *Neuroscience* 118: 107–113, 2003.
60. Stephenson D, Rash K, Smalstig B, Roberts E, Johnstone E, Sharp J, Panetta J, Little S, Kramer R, and Clemens J. Cytosolic phospholipase A₂ is induced in reactive glia following different forms of neurodegeneration. *Glia* 27: 110–128, 1999.
61. Uchida K. Current status of acrolein as a lipid peroxidation product. *Trends Cardiovasc Med* 9: 109–113, 1999.
62. Walton M, Sirimanne E, Williams C, Gluckman PD, Keelan J, Mitchell MD, and Dragunow M. Prostaglandin H synthase-2 and cPLA₂ in the hypoxic-ischemic brain: role in neuronal death or survival? *Mol Brain Res* 50: 165–170, 1997.
63. Woo CH, Eom YW, Yoo MH, You HJ, Han HJ, Song WK, Yoo YJ, Chun JS, and Kim JH. Tumor necrosis factor- α generates reactive oxygen species via a cytosolic phospholipase A₂-linked cascade. *J Biol Chem* 275: 32357–32362, 2000.
64. Wu YL, Jiang XR, Newland AC, and Kelsey SM. Failure to activate cytosolic phospholipase A₂ causes TNF resistance in human leukemic cells. *J Immunol* 160: 5929–5935, 1998.
65. Yang HC, Mosior M, Johnson CA, Chen Y, and Dennis EA. Group-specific assays that distinguish between the four major types of mammalian phospholipase A₂. *Anal Biochem* 269: 278–288, 1999.
66. Ying WH, Han SK, Miller JW, and Swanson RA. Acidosis potentiates oxidative neuronal death by multiple mechanisms. *J Neurochem* 73: 1549–1556, 1999.
67. Zhang YP, Lemasters J, and Herman B. Secretory group IIA phospholipase A₂ generates anti-apoptotic survival signals in kidney fibroblasts. *J Biol Chem* 274: 27726–27733, 1999.

Address reprint requests to:
 Dr. Rao Muralikrishna Adibhatla
 Department of Neurological Surgery
 H4-330, Clinical Science Center
 600 Highland Avenue
 University of Wisconsin-Madison
 Madison, WI 53792-3232

E-mail: adibhatl@neurosurg.wisc.edu

Received for publication January 14, 2003; accepted June 30, 2003.

This article has been cited by:

1. Pratima Tripathi, Pachiyappan Kamarajan, Bagganahalli S. Somashekar, Neil MacKinnon, Arul M. Chinnaiyan, Yvonne L. Kapila, Thekkelnaycke M. Rajendiran, Ayyalusamy Ramamoorthy. 2012. Delineating metabolic signatures of head and neck squamous cell carcinoma: Phospholipase A2, a potential therapeutic target. *The International Journal of Biochemistry & Cell Biology* **44**:11, 1852-1861. [[CrossRef](#)]
2. Rodrigo Herrera-Molina, Betsi Flores, Juan A. Orellana, Rommy von Bernhardt. 2012. Modulation of interferon- γ -induced glial cell activation by transforming growth factor β 1: A role for STAT1 and MAPK pathways. *Journal of Neurochemistry* **123**:1, 113-123. [[CrossRef](#)]
3. Hay-Yan J. Wang, Hsuan-Wen Wu, Ping-Ju Tsai, Cheng Bin Liu. 2012. MALDI-mass spectrometry imaging of desalted rat brain sections reveals ischemia-mediated changes of lipids. *Analytical and Bioanalytical Chemistry* **404**:1, 113-124. [[CrossRef](#)]
4. Keita Shibata, Terumasa Hashimoto, Koji Nobe, Keiji Hasumi, Kazuo Honda. 2011. Neuroprotective mechanisms of SMTP-7 in cerebral infarction model in mice. *Naunyn-Schmiedeberg's Archives of Pharmacology* **384**:1, 103-108. [[CrossRef](#)]
5. Mohamed A. Abdel-Rahman, Ismail M. Abdel-Nabi, Mohamed S. El-Naggar, Osama A. Abbas, Peter N. Strong. 2011. Intraspecific variation in the venom of the vermivorous cone snail *Conus vexillum*. *Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology* . [[CrossRef](#)]
6. Giselle Pentón-Rol, Javier Marín-Prida, Gilberto Pardo-Andreu, Gregorio Martínez-Sánchez, Emilio Felino Acosta-Medina, Alain Valdivia-Acosta, Nielsen Lagumersindez-Denis, Efraín Rodríguez-Jiménez, Alexey Llópiz-Arzuaga, Pedro Antonio López-Saura, Gerardo Guillén-Nieto, Eduardo Pentón-Arias. 2011. C-Phycocyanin is neuroprotective against global cerebral ischemia/reperfusion injury in gerbils. *Brain Research Bulletin* . [[CrossRef](#)]
7. Cameron Rink , Savita Khanna . 2011. Significance of Brain Tissue Oxygenation and the Arachidonic Acid Cascade in Stroke. *Antioxidants & Redox Signaling* **14**:10, 1889-1903. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
8. Hai Chen , Hideyuki Yoshioka , Gab Seok Kim , Joo Eun Jung , Nobuya Okami , Hiroyuki Sakata , Carolina M. Maier , Purnima Narasimhan , Christina E. Goeders , Pak H. Chan . 2011. Oxidative Stress in Ischemic Brain Damage: Mechanisms of Cell Death and Potential Molecular Targets for Neuroprotection. *Antioxidants & Redox Signaling* **14**:8, 1505-1517. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
9. S. Ghosh, N. Das, A.K. Mandal, S.R. Dungdung, S. Sarkar. 2010. Mannosylated liposomal cytidine 5' diphosphocholine prevent age related global moderate cerebral ischemia reperfusion induced mitochondrial cytochrome c release in aged rat brain. *Neuroscience* **171**:4, 1287-1299. [[CrossRef](#)]
10. Gianfrancesco Goracci, Monica Ferrini, Vincenza Nardicchi. 2010. Low Molecular Weight Phospholipases A2 in Mammalian Brain and Neural Cells: Roles in Functions and Dysfunctions. *Molecular Neurobiology* **41**:2-3, 274-289. [[CrossRef](#)]
11. Rao Muralikrishna Adibhatla , James Franklin Hatcher . 2010. Lipid Oxidation and Peroxidation in CNS Health and Disease: From Molecular Mechanisms to Therapeutic Opportunities. *Antioxidants & Redox Signaling* **12**:1, 125-169. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
12. Mark P. Mattson. 2009. Roles of the lipid peroxidation product 4-hydroxynonenal in obesity, the metabolic syndrome, and associated vascular and neurodegenerative disorders. *Experimental Gerontology* **44**:10, 625-633. [[CrossRef](#)]
13. Myron D. Ginsberg. 2008. Neuroprotection for ischemic stroke: Past, present and future. *Neuropharmacology* **55**:3, 363-389. [[CrossRef](#)]
14. Rao Muralikrishna Adibhatla, J.F. Hatcher. 2008. Phospholipase A 2 , reactive oxygen species, and lipid peroxidation in CNS pathologies. *BMB Reports* **41**:8, 560-567. [[CrossRef](#)]

15. T.T. Hong Duong, Shane Antao, Natasha A. Ellis, Simon J. Myers, Paul K. Witting. 2008. Supplementation with a synthetic polyphenol limits oxidative stress and enhances neuronal cell viability in response to hypoxia–re-oxygenation injury. *Brain Research* **1219**, 8-18. [[CrossRef](#)]
16. Melanie Y. White, Alistair V. G. Edwards, Stuart J. Cordwell, Jennifer E. Van Eyk. 2008. Mitochondria: A mirror into cellular dysfunction in heart disease. *PROTEOMICS – CLINICAL APPLICATIONS* **2**:6, 845-861. [[CrossRef](#)]
17. In Koo Hwang, Ki-Yeon Yoo, Dae Won Kim, So Young Kim, Jun Hong Park, Zae Young Ryoo, Joon Kim, Soo Young Choi, Moo-Ho Won. 2008. Ischemia-induced ribosomal protein S3 expressional changes and the neuroprotective effect against experimental cerebral ischemic damage. *Journal of Neuroscience Research* **86**:8, 1823-1835. [[CrossRef](#)]
18. Yasufumi Tanaka, Yusuke Moritoh, Nobuhiko Miwa. 2007. Age-dependent telomere-shortening is repressed by phosphorylated #-tocopherol together with cellular longevity and intracellular oxidative-stress reduction in human brain microvascular endotheliocytes. *Journal of Cellular Biochemistry* **102**:3, 689-703. [[CrossRef](#)]
19. Donggeun Sul, Hyunsook Kim, Eunha Oh, Sohee Phark, Eunkyung Cho, Seonyoung Choi, Hyung-Sik Kang, Eun-Mi Kim, Kwang-Woo Hwang, Woon-Won Jung. 2007. Gene expression profiling in lung tissues from rats exposed to formaldehyde. *Archives of Toxicology* **81**:8, 589-597. [[CrossRef](#)]
20. Akhlaq A. Farooqui, Lloyd A. Horrocks, Tahira Farooqui. 2007. Interactions between neural membrane glycerophospholipid and sphingolipid mediators: A recipe for neural cell survival or suicide. *Journal of Neuroscience Research* **85**:9, 1834-1850. [[CrossRef](#)]
21. Leonid F. Dmitriev. 2007. Shortage of Lipid-radical Cycles in Membranes as a Possible Prime Cause of Energetic Failure in Aging and Alzheimer Disease. *Neurochemical Research* **32**:8, 1278-1291. [[CrossRef](#)]
22. Rao Muralikrishna Adibhatla, J.F. Hatcher. 2007. Secretory phospholipase A2 IIA is up-regulated by TNF-# and IL-1#/# after transient focal cerebral ischemia in rat. *Brain Research* **1134**, 199-205. [[CrossRef](#)]
23. Frank Schuettauf, Robert Rejdak, Sebastian Thaler, Sylvia Bolz, Cristiana Lehaci, Anna Mankowska, Tomasz Zarnowski, Anselm Junemann, Zbigniew Zagorski, Eberhart Zrenner. 2006. Citicoline and lithium rescue retinal ganglion cells following partial optic nerve crush in the rat. *Experimental Eye Research* **83**:5, 1128-1134. [[CrossRef](#)]
24. Neslihan Yücel, Süleyman R. Çayl#, Özkan Ate#, Ne#e Karada#, Serpil F#rat, Yusuf Türköz. 2006. Evaluation of the Neuroprotective Effects of Citicoline after Experimental Spinal Cord Injury: Improved Behavioral and Neuroanatomical Recovery. *Neurochemical Research* **31**:6, 767-775. [[CrossRef](#)]
25. Rao Muralikrishna Adibhatla, J. F. Hatcher, R. J. Dempsey. 2006. Lipids and lipidomics in brain injury and diseases. *The AAPS Journal* **8**:2, E314-E321. [[CrossRef](#)]
26. Ben S. Rayner, T. T. Hong Duong, Simon J. Myers, Paul K. Witting. 2006. Protective effect of a synthetic anti-oxidant on neuronal cell apoptosis resulting from experimental hypoxia re-oxygenation injury. *Journal of Neurochemistry* **97**:1, 211-221. [[CrossRef](#)]
27. Abdurrahman Al Asmari, Khalaf Al Moutaery, Rajamohamed Abbas Manthari, Haseeb Ahmad Khan. 2006. Time-course of lipid peroxidation in different organs of mice treated with Echis pyramidium snake venom. *Journal of Biochemical and Molecular Toxicology* **20**:2, 93-95. [[CrossRef](#)]
28. M GRUBER, G WIESNER, R BURGER, R LINDNER. 2006. The salicylate trapping method: Is oxidation of salicylic acid solution oxygen and time dependent and metal catalysed?. *Journal of Chromatography B* **831**:1-2, 320-323. [[CrossRef](#)]
29. Rao Muralikrishna Adibhatla, J.F. Hatcher. 2006. Phospholipase A2, reactive oxygen species, and lipid peroxidation in cerebral ischemia. *Free Radical Biology and Medicine* **40**:3, 376-387. [[CrossRef](#)]
30. RM Adibhatla, J Hatcher, R Dempsey. 2006. Lipids and Lipidomics in Brain Injury and Diseases. *The AAPS Journal* **08**:02, E314. [[CrossRef](#)]

31. R MURALIKRISHNAADIBHATLA, J HATCHER, K TUREYEN. 2005. CDP-choline liposomes provide significant reduction in infarction over free CDP-choline in stroke. *Brain Research* **1058**:1-2, 193-197. [[CrossRef](#)]
32. G.D. Zeevalk , L.P. Bernard , C. Song , M. Gluck , J. Ehrhart . 2005. Mitochondrial Inhibition and Oxidative Stress: Reciprocating Players in Neurodegeneration. *Antioxidants & Redox Signaling* **7**:9-10, 1117-1139. [[Abstract](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
33. Rao Muralikrishna Adibhatla, J. F. Hatcher. 2005. Cytidine 5'-Diphosphocholine (CDP-Choline) in Stroke and Other CNS Disorders. *Neurochemical Research* **30**:1, 15-23. [[CrossRef](#)]
34. Rao Muralikrishna Adibhatla, James F. Hatcher, Robert J. Dempsey. 2004. Cytidine-5'-diphosphocholine affects CTP-phosphocholine cytidyltransferase and lyso-phosphatidylcholine after transient brain ischemia. *Journal of Neuroscience Research* **76**:3, 390-396. [[CrossRef](#)]
35. James L. Franklin . 2003. Programmed Neuronal Death. *Antioxidants & Redox Signaling* **5**:5, 583-587. [[Citation](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
36. Rao Muralikrishna Adibhatla, James F. Hatcher. 2003. Citicoline decreases phospholipase A2 stimulation and hydroxyl radical generation in transient cerebral ischemia. *Journal of Neuroscience Research* **73**:3, 308-315. [[CrossRef](#)]